Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
Posted: September 27, 2024 at 2:51 am
TARRYTOWN, N.Y., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2024 financial and operating results on Thursday, October 31, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Go here to read the rest:
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
Posted in Global News Feed
Comments Off on Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
Better Choice Company to Present at the 2024 ThinkEquity Conference and Provides Detail on Sales in China and the Acquisition of SRx Health
Posted: September 27, 2024 at 2:51 am
Sustained Sales Momentum in China in Q3 Following 37% Sequential Growth in Q2
See original here:
Better Choice Company to Present at the 2024 ThinkEquity Conference and Provides Detail on Sales in China and the Acquisition of SRx Health
Posted in Global News Feed
Comments Off on Better Choice Company to Present at the 2024 ThinkEquity Conference and Provides Detail on Sales in China and the Acquisition of SRx Health
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
Posted: September 27, 2024 at 2:51 am
-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April and July-
Visit link:
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
Posted in Global News Feed
Comments Off on Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on…
Posted: September 27, 2024 at 2:51 am
DURHAM, N.C., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced it will host a virtual KOL event on Monday, September 30, 2024 at 8:00 AM ET. To register, click here.
Posted in Global News Feed
Comments Off on Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV™) in Vascular Trauma Treatment on…
Medicenna Announces Results of Annual Meeting of Shareholders
Posted: September 27, 2024 at 2:51 am
TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced the voting results from the Company’s annual meeting of shareholders held today, September 26, 2024 (the “Meeting”).
See original here:
Medicenna Announces Results of Annual Meeting of Shareholders
Posted in Global News Feed
Comments Off on Medicenna Announces Results of Annual Meeting of Shareholders
Qualigen Therapeutics, Inc. Announces management changes.
Posted: September 27, 2024 at 2:51 am
CARLSBAD, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced on September 23, 2024, Mr. Michael Poirier, notified the board of directors of the Company (the Board") of his intention to resign as chief executive officer and Chairman of the Board of the Company, effective immediately. On the same date, Mr. Christopher Lotz, Chief Financial Office also tendered his resignation from the company, effective immediately. Both resignations were attributed to disagreements with the Company regarding its future direction and strategic initiatives.
More:
Qualigen Therapeutics, Inc. Announces management changes.
Posted in Global News Feed
Comments Off on Qualigen Therapeutics, Inc. Announces management changes.
Cassava Sciences Resolves SEC Investigation
Posted: September 27, 2024 at 2:51 am
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) of negligence-based disclosure charges that resolve a previously-disclosed SEC investigation into statements made by the Company pertaining to the results of its 2020 Phase 2b clinical trial of simufilam and related matters. Two former senior employees of the Company also settled negligence-based disclosure charges brought by the SEC.
Continue reading here:
Cassava Sciences Resolves SEC Investigation
Posted in Global News Feed
Comments Off on Cassava Sciences Resolves SEC Investigation
Virbac 2024 half-year results
Posted: September 15, 2024 at 2:45 am
1adjusted current operating income corresponds to the “current operating income before amortization of assets arising from acquisitions”2growth at constant exchange rates and scope corresponds to organic growth of sales, excluding exchange rate variations, by calculating the indicator for the financial year in question and the indicator for the previous financial year on the basis of identical exchange rates (the exchange rate used is the previous financial year), and excluding material change in scope, by calculating the indicator for the financial year in question on the basis of the scope of consolidation for the previous financial year. This change is calculated on the actual scope of consolidation, including the impact of acquisitions (Globion and Sasaeah), for which the indicator in question is calculated on the basis of the previous year's exchange rate3net debt corresponds to current (€187.3 million) and non-current (€187.4 million) financial liabilities as well as a lease obligation related to the application of IFRS 16 (€37 million), less the cash position and cash equivalents (€156.8 million) as published in the statement of financial position4net cash position as of December 31, 20235operating cash flow corresponds to adjusted current operating income (€150.4 million) restated for items having no impact on the cash position as well as impact arising from asset disposal. This restates depreciation and amortization of fixed assets before acquisitions for €22.5 million (comprising €24.2 million in depreciation and amortization of fixed assets and provisions, and €-1.6 million in amortization of assets from acquisitions), as well as non-current income and expenses (€2 million), other non-cash income and expenses (€0.4 million), and impact of disposals (€1.3 million)
Original post:
Virbac 2024 half-year results
Posted in Global News Feed
Comments Off on Virbac 2024 half-year results
Virbac: Information on the departure of Sébastien Huron
Posted: September 15, 2024 at 2:45 am
At its meeting on September 13, 2024, the board of directors acknowledged the resignation of Sébastien Huron, effective as of September 27, 2024, from his positions as chief executive officer of Virbac and director of Virbac Limited (UK).
Continued here:
Virbac: Information on the departure of Sébastien Huron
Posted in Global News Feed
Comments Off on Virbac: Information on the departure of Sébastien Huron
Virbac : the board of directors announces a capital reduction through cancellation of treasury shares
Posted: September 15, 2024 at 2:45 am
Focusing on animal health, from the beginningAt Virbac, we provide innovative solutions to veterinarians, farmers and animal owners in more than 100 countries around the world. Covering more than 50 species, our range of products and services enables to diagnose, prevent and treat the majority of pathologies. Every day, we are committed to improving animals’ quality of life and to shaping together the future of animal health.
Read the rest here:
Virbac : the board of directors announces a capital reduction through cancellation of treasury shares
Posted in Global News Feed
Comments Off on Virbac : the board of directors announces a capital reduction through cancellation of treasury shares
